Abstract Purpose: Megalin, an endocytic receptor expressed by prostate epithelial cells, can internalize biologically active androgens bound to sex hormone binding globulin. Genetic variation within megalin could potentially influence levels of steroid hormone uptake. Experimental Design: Forty haplotype-tagging single-nucleotide polymorphisms (htSNP) were analyzed in a population-based, case-control study of 553 Caucasian men who were diagnosed with prostate cancer between the ages of 40 and 64 years from the Seattle-Puget Sound region and 534 control men. Prostate cancer risk was estimated using adjusted unconditional logistic regression for both individual SNPs and haplotypes. Risks of disease recurrence/ progression and prostate-specific cancer mortality were estimated using Cox proportional hazards regression. Results: We found no strong evidence of altered risk of developing prostate cancer for any of the htSNPs when they were assessed individually or in haplotypes. However, three htSNPs were significantly associated with both disease recurrence/progression and mortality. Risk of recurrence/progression alone was also associated with five additional htSNPs, and six other htSNPS showed evidence of modification by primary androgen deprivation therapy. Two additional htSNPs were significantly associated with altered risk of death from prostate cancer. Conclusions: Preliminary results suggest that common genetic variation within the megalin gene could alter both risk of recurrence/progression and prostate-specific cancer mortality. In addition, androgen deprivation therapy effectiveness may be modified by the activity of this gene. To our knowledge, this is the first study that has examined polymorphisms within the megalin gene for associations with prostate cancer risk and outcomes.
Androgens are believed to contribute to both the etiology and progression of prostate cancer (1) . Previously, it was thought that the only way the androgen hormone entered the cell and became biologically active was after disassociation from its plasma carrier protein, sex hormone binding globulin, and subsequent internalization of the lipophilic compound via free diffusion (2) . A recent study by Hammes and colleagues (3) showed that megalin, a member of the LDL receptor gene family located on chromosome 2q24-q31, may play a role in the internalization of androgen into the prostatic cell. These researchers showed that megalin, a multiligand endocytic receptor, carries a specific binding site for androgen still bound to sex hormone binding globulin and serves as an active uptake mechanism of the entire steroid hormone complex. The role of megalin in the uptake of androgen in the mature healthy human prostate cell is not known, but our preliminary immunohistochemical assay studies of megalin gene expression have found increased levels of the protein in malignant relative to benign prostate cells. 5 Polymorphisms within the megalin gene [low density lipoprotein -related protein 2 (LRP2)] could potentially alter the activity of the encoded protein to either promote or inhibit active transport of androgen into the prostate cell, resulting in a phenotype that has altered levels of androgen in the prostate cell. Whether this phenotype would have greater effect on normal versus malignant prostate cells is difficult to predict. If' megalin does in fact play a significant role in the internalization of androgen in normal mature prostate cells, then genetic variation could potentially affect the risk of developing prostate cancer. It is also plausible that prostate cancer cells may benefit from increased internalization of androgens via the active transport mechanism of megalin (4) . Indeed, our immunohistochemical assay evidence does support a role of megalin in tumor progression. This lends credence to the hypothesis that a megalin phenotype that alters the uptake of androgen could modify the progression from a localized androgen-dependent state into the androgen-independent and metastatic forms of prostate cancer. This association could be observed in either the risks of clinically diagnosed aggressive forms of prostate cancer or by disease outcomes. In addition, changes in protein function mediated by genetic variants could theoretically modify the reaction of prostate cells to androgen deprivation therapy (ADT). The goal of this study was to measure common genetic variation within megalin and to explore potential associations with disease risk, recurrence/progression, prostatespecific mortality, and possible interactions with primary ADT in a population-based, case-control study.
Materials and Methods
Study population. Study subjects were enrolled in a populationbased prostate cancer case-control study that has previously been described (5) . Prostate cancer cases were identified from the metropolitan Seattle-Puget Sound population-based tumor registry that is operated as part of the National Cancer Institute Surveillance, Epidemiology, and End Results program. The Surveillance, Epidemiology, and End Results registry also provided information on tumor characteristics, primary therapy, and vital status. Underlying cause of death was confirmed from death certificates. Eligible individuals were Caucasian or African American men, ages 40 to 64 y, who were newly diagnosed with histologically confirmed prostate cancer between January 1, 1993 and December 31, 1996. Of the 916 men eligible for the study, 752 (82.1%) completed structured in-person interviews. We obtained peripheral blood leukocyte samples yielding sufficient DNA for genotyping from 585 (77.8%) of the interviewed cases. Analysis was further limited to Caucasian men, bringing the total number of cases to 553 (94.5%).
Controls were identified through random digit telephone dialing using a clustering factor of five residences per sampling unit. Controls were frequency matched to cases by age (same 5-year group). Eligible controls were Caucasian or African American men, ages 40 to 64 y at the reference date, with no history of prostate cancer. Complete household census information was obtained for 94% of the 21,116 residential telephone numbers contacted. Of the 941 men who were identified and agreed to participate, 703 (74.7%) were interviewed, making the overall level of participation 70.2% (94% Â 74.7%). From these potential controls, our analysis was limited to the 549 (78.1%) from whom we had sufficient DNA for genotyping. Analysis was further restricted to Caucasian men, bringing the total number of controls to 534 (97%).
Cases and controls completed detailed in-person interviews covering demographic, medical, lifestyle, and family cancer history conducted by trained male interviewers. Blood specimens were processed and DNA isolated using standard protocols (6) . There were no differences between the nongenotyped and genotyped cases and controls with respect to age, race, family history of prostate cancer, or clinical characteristics of the patients. In January 2004, a self-administered follow-up questionnaire collecting information on quality of life, secondary therapies, follow-up prostate-specific antigen (PSA) results, and prostate cancer recurrence/progression was sent to the cases. Of the 630 cases who were alive and previously consented to future contact, the survey was completed by 520 (82.4%). Of these respondents, 405 (77.9%) had DNA and were Caucasian. There were no differences between follow-up survey respondents versus nonrespondents with respect to tumor characteristics or primary therapy. This study was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board and genotyping was approved by the Internal Review Board of the National Human Genome Research Institute.
Single-nucleotide polymorphism selection and genotyping. Singlenucleotide polymorphisms (SNP) that captured the genetic variability in the gene were selected using publicly available data from the HapMap consortium 6 from a 248-kb region that comprised the LRP2 locus and 13 kb of the 5 ¶ end/promoter (from 169,804,367 to 170,048,683 in National Center for Biotechnology Information Build 35). There were 219 SNPs with minor allele frequencies >5% in the Caucasian HapMap data set. Haploview software version 3.11 was used to generate pairwise linkage disequilibrium estimates and define haplotype blocks using criteria outlined first by Gabriel and colleagues and then by the Solid Spline approach (7, 8) . The user-defined linkage disequilibrium criteria for defining the blocks were fraction of informative pairwise comparisons z0.95 and D ¶ > 0.8. This excludes SNPs with a minor allele frequency <5% by default. A total of 40 haplotype tagging SNPs (htSNP) were then selected to capture the variation within each block and then regions in between blocks (9). We defined common haplotypes as those with a frequency of >5%. The set of optimal htSNPs included three nonsynonymous SNPs that were forced into the htSNP selection.
The Applied Biosystems SNPlex Genotyping System was used to genotype SNPs in individual DNA samples. Proprietary GeneMapper software was used for calling alleles. 7 Discrimination of the specific SNP allele is carried out with the Applied Biosystems 3730xl DNA Analyzer and is based on the presence of a unique sequence assigned to the original allele-specific oligonucleotide.
Quality control included genotyping of 76 blind duplicate samples, which revealed 99% agreement on genotyping calls across all SNPs assayed. In addition, each batch of DNA aliquots genotyped incorporated similar numbers of case and control samples, and laboratory personnel were blinded to the case-control status of samples. The overall call rate was 99.0%. Subjects had to have at least 75%, or 30 of the 40 SNPs, successfully genotyped to be included in the study. Of the 56 case specimens included who did not have completely successful genotyping, 34 had only one SNP with unknown genotype, 12 had two SNPs with unknown genotype, and 10 had three to nine SNPs with unknown genotypes. Of the 30 controls who did not have complete genotyping, 16 had only one SNP with unknown genotype, 6 had two SNPs with unknown genotype, and 8 had three to nine SNPs with unknown genotypes.
Statistical analysis. SNP genotype frequencies were examined for Hardy-Weinberg equilibrium using the m 2 statistics. Data were analyzed using unconditional logistic regression to calculate odds ratios as estimates of the relative risk of prostate cancer associated with any given individual htSNP. For each htSNP, we classified carriers of the variant or less common allele as the exposure group and then used both dominant and codominant models, excepting the polymorphic loci for which no individuals were homozygous for the variant genotype. We included the design variable of age in all regression models. We also assessed possible confounding effects of first-degree family history of prostate cancer, PSA testing history (none versus any PSA test done in the previous 5 y), history of benign prostatic hyperplasia (none, diagnosis V2 y before reference date, diagnosis >2 y before reference date), and body mass index (<25, 25-29, z30 kg/m 2 ). Because adjustment for none of these variables appreciably altered risk estimates, we did not include them as covariates. Trend tests were used to assess gene dosage and global P values were estimated to assess overall gene effect. Associations with individual htSNPs according to Gleason score [2-6 or 7 (3 + 4) versus 7 (4 + 3) or 8-10], tumor stage (local versus regional/distant), and a composite prostate cancer aggressiveness score were examined using polytomous regression. Classification parameters of the composite ''nonaggressive'' phenotype included diagnosis at local stage, and Gleason score of 2 to 6 or 7 (3 + 4), and serum PSA <20 ng/mL, whereas the ''aggressive'' phenotype included diagnosis at regional/distant stage, or Gleason score 7 (4 + 3) or 8 to 10, or serum PSA z20 ng/mL.
Because the htSNPs were chosen to represent haplotype variation, it is necessary to include both individual SNP and haplotype analyses for a complete assessment of genetic variation with disease risk. Two haplotype analyses were carried out. In the first, haplotype risk was assessed within each block using criteria defined by Gabriel and colleagues (7) . Using data from control subjects, Haploview software version 3.2 was used to estimate pairwise linkage disequilibrium between the htSNPs and define haplotype blocks. In the second analysis, haplotype risk was assessed for a haplotype containing only htSNPs, which showed an individual significant association with prostate cancer risk. Risk was assessed using Haplostat software (version 1.2.1) 8 for R (version 2.1.0), 9 which uses the expectation-maximization algorithm to estimate haplotype frequencies and an iterative two-step expectationmaximization model to estimate the association between individual haplotypes and risk assuming an additive model (10) . Overall differences in risk of prostate cancer across haplotypes were assessed using global score test adjusted for age (11) . Only haplotypes with estimated frequencies of >5% were included.
To examine associations between individual htSNPs with prostate cancer recurrence/progression and prostate cancer mortality, we used Cox proportional hazards regression models adjusting for age, Gleason score, stage at diagnosis, and diagnostic PSA level. For estimating risk in the recurrence/progression model, the time-dependent variable was defined as time from diagnosis to the first self-reported evidence of development of metastasis. This variable was calculated using the data from the self-administered follow-up questionnaire as previously described (12) . The censoring date for cases without a metastasis event was the date that their follow-up questionnaire was returned. Cases who had an initial diagnosis of metastatic disease were excluded from the analysis (n = 5) as were cases who were alive and did not fill out a follow-up questionnaire (n = 83). To account for cases diagnosed with localized or regional disease who died of metastatic prostate cancer before the follow-up survey was administered, the proportional hazards model was weighted. The weights were the inverse of the probability of having a metastasis date for men with a metastatic event and 1.0 for the men who were censored (13) . For calculation of prostate-specific mortality, the time-dependent variable was defined as the time from We also assessed the possibility of an interaction between genotype and ADT with both disease recurrence/progression and survival. Using both data from the Surveillance, Epidemiology, and End Results registry and the self-report questionnaire, we defined cases who received androgen deprivation shots, pills, and/or orchiectomy within 12 mo of initial diagnosis as having received primary ADT. Due to small numbers of cases receiving primary ADT overall (n = 94), we limited both our mortality and recurrence/progression proportional hazards models to risk estimates assuming a dominant genetic model, combining heterozygotes and homozygous variants as the comparison group. Models with and without interaction terms were compared using the likelihood ratio test.
In an effort to account for multiple comparisons, the false discovery rate was used to calculate corrected critical P value to evaluate the robustness of all risk estimates (14) . After consideration of SNP genotypes individually, all significant SNPs were included in a stepwise selection model using Akaike's Information Criterion to select the most parsimonious model (15) . SNPs that remained significant (P V 0.05) after adjustment for each other were included in the final model (16) . Both forward and backward selection models were compared, with equivalent results. All analyses were done using the STATA statistical package (version 9.2, STATA Corp.).
Results
Cases and controls were similar in age (mean: cases, 57 years; controls, 57 years). Cases were more likely to report a family history of prostate cancer, history of benign prostatic hyperplasia, and history of PSA tests ( Table 1 ). The majority of prostate cancers were local stage tumors with low/moderate Gleason scores. All SNPs included in this study were statistically consistent (P > 0.05) with the Hardy-Weinberg equilibrium.
There was no strong evidence of altered risk of developing prostate cancer for any of the htSNPs evaluated (Table 2) . Two SNPs (rs3944004 and rs2268373) showed slightly lower relative risks of prostate cancer for the homozygous variant carriers versus homozygous wild-type carriers. Two SNPs (rs2239598 and rs831003) showed slightly increased relative risks for the heterozygote carriers as compared with homozygous wild-type carriers. However, the P for trend for all four of these SNPs was >0.05, and after adjustment for multiple comparisons none of these associations remained significant. When we assessed risk estimates by measures of tumor aggressiveness (Gleason score, stage, and composite score), we found no differences in risk estimates for any of the polymorphisms examined.
Within the 40 htSNPs included in this study, we defined 8 haplotype blocks (A-H; see Table 2 ) ranging from two to five htSNPs. Thirteen htSNPs did not fall into any haplotype block structure. We found no evidence of altered relative risks of prostate cancer for any of the haplotypes in any of the blocks. The four SNPs that showed slightly altered risks at the individual level (rs3944004, rs2268373, rs2239595, and rs831003) displayed no evidence of altered risks for prostate cancer when a haplotype containing only these four htSNPs was considered.
There were 86 cases with physician-diagnosed recurrence/ progression, with an average of 8.8 years of follow-up (range, 0.2-11.9 years) after diagnosis. Of these 86 cases, 67 (78%) were diagnosed at low/moderate Gleason score, 55 (64%) were diagnosed at a localized stage, and 14 (16%) were treated with primary ADT. Eight htSNPs showed altered risks of disease recurrence/progression overall (Table 3) . When these SNPs were adjusted for multiple comparisons, only three SNPs (rs830994, rs830995, and rs831003), all within the same haplotype block ''E,'' retained significance. We then considered all eight SNPs and then only the three block ''E'' SNPs using stepwise regression and found that only rs830994 remained significant at P = 0.001, independent of all other SNPs in the model. An additional six htSNPs, although not showing altered risks for all cases combined, did show some evidence of different risks of recurrence/progression by ADT (Table 3) .
There were 33 cases who died of prostate cancer in the average 10.4 years of follow-up (range, 1.3-13.4 years). Of these 33 cases, 12 (36%) were diagnosed at low/moderate Gleason score [2-6 or 7 (3 + 4)], 6 (18%) were diagnosed at a localized Abbreviation: NS, not significant. * Includes only subjects who completed the self-administered follow-up questionnaire. c Category includes cases who received androgen deprivation shots, pills, and/or orchiectomy within 12 mo of initial diagnosis date. b P value based on the likelihood ratio test comparing models with and without an interaction term.
x Category includes a self-reported physician's diagnosis of prostate cancer recurrence/progression, a positive bone scan, biopsy, or magnetic resonance imaging showing cancer after primary treatment, or a PSA value >0.2 ng/mL after radical prostatectomy. k Cox proportional hazards models are adjusted for age, Gleason score, tumor stage at diagnosis, and PSA screening history. Hazard ratios with significance at P V 0.05 are in boldface. { These htSNPs are also associated with altered risks of prostate-specific cancer mortality by genotype. ** These associations remain significant after adjustment for multiple comparisons. c c These associations remain significant in a stepwise regression model. b b This is a nonsynonymous SNP.
megalin gene and the lack of any previously published findings on functional polymorphisms, we elected to use the haplotype tagging approach. This was a cost-effective means to identify susceptibility alleles across the entire gene region.
In conclusion, although this study does not support a role between megalin polymorphisms and the risk of developing prostate cancer, several polymorphisms seem to play a role in the prostate cancer outcomes following diagnosis. Both the htSNPs identified in this study and SNPs in linkage disequilibrium with these htSNPS need to be examined to determine if, and how, they affect megalin protein function. A true test for the robustness of our findings will be replication in a larger data set. In addition, a larger study may be able to expand on the initial findings here, suggesting a role for megalin polymorphisms and outcomes associated with use of ADT.
